Felipe Couñago: Better Risk Stratification in Prostate Cancer – ADC + PSA Post RT+ADT
Felipe Couñago, National Clinical Director of GenesisCare Spain, shared a post on X:
“New in Biomedicines
ADC (mpMRI) + PSA at 6m after RT+ADT leads to better risk stratification in Prostate Cancer. Congrats to all authors!”
Title: Integrating Apparent Diffusion Coefficient and Prostate-Specific Antigen as Prognostic Factors of Treatment Response to Androgen Deprivation Therapy and Radiotherapy in Prostate Cancer
Authors: Victor Duque-Santana, Julio Fernandez, Fernando López-Campos, Ana Diaz-Gavela, Manuel Recio, Luis L. Guerrero, Marina Peña, Sofia Sanchez, Israel J. Thuissard, Cristina Andreu-Vázquez, David Sanz-Rosa, Giulia Marvaso, Alfonso Gómez-Iturriaga, Thomas Zilli, Elia Del Cerro, Felipe Couñago
Read the Full Article.
More posts featuring Felipe Couñago.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023